Katherine E. Fleming-Dutra
YOU?
Author Swipe
View article: Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis Open
View article: Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season Open
View article: Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach Open
View article: 426. Effectiveness of Updated (2023-2024) Monovalent COVID-19 Vaccines – VISION Network, September 2023-March 2024
426. Effectiveness of Updated (2023-2024) Monovalent COVID-19 Vaccines – VISION Network, September 2023-March 2024 Open
Background In September 2023, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccines for use in persons ≥6 months for preven…
View article: Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 Open
View article: Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025 Open
COVID-19 vaccination provides additional protection against severe COVID-19-associated illness and death. Since September 2023, 2023-2024 Formula monovalent XBB.1-strain COVID-19 vaccines have been recommended for use in the United States …
View article: Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022–August 2023
Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022–August 2023 Open
Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023–2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people, furthe…
View article: Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 Open
Respiratory syncytial virus (RSV) is a major cause of respiratory illness and hospitalization in older adults during fall and winter in the United States. The 2023-2024 RSV season was the first during which RSV vaccination was recommended …
View article: Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 Open
COVID-19 remains an important public health threat, despite overall decreases in COVID-19-related severe disease since the start of the COVID-19 pandemic. COVID-19-associated hospitalization rates remain higher among adults aged ≥65 years …
View article: Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024 Open
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-…
View article: Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024 Open
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estima…
View article: Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024
Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 Open
On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to prevent COVID-19, including …
View article: Development of COVID-19 vaccine policy — United States, 2020–2023
Development of COVID-19 vaccine policy — United States, 2020–2023 Open
View article: Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions
Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions Open
COVID-19 vaccines were originally authorized in the United States in December 2020 on the basis of safety, immunogenicity, and clinical efficacy data from randomized controlled trials (RCTs). However, real-world vaccine effectiveness (VE) …
View article: 2365. Effectiveness of COVID-19 Vaccines Against Medically Attended COVID-19 in Pregnant Persons Within the VISION Network, December 2021 - April 2023
2365. Effectiveness of COVID-19 Vaccines Against Medically Attended COVID-19 in Pregnant Persons Within the VISION Network, December 2021 - April 2023 Open
Background Pregnant people have an increased risk of severe COVID-19, including hospitalization and critical illness. Currently, pregnant people are recommended to receive the same vaccinations as non-pregnant people of the same age and un…
View article: 1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody Open
Background RSV results in substantial morbidity among young infants. Maternal RSV vaccines and monoclonal antibodies against RSV for infants have been developed, but little is known about acceptance of these products. Methods We conducted …
View article: 2081. COVID-19 mRNA Vaccine Effectiveness against Hospitalizations among U.S. Children and Adolescents During Omicron Variant Predominance
2081. COVID-19 mRNA Vaccine Effectiveness against Hospitalizations among U.S. Children and Adolescents During Omicron Variant Predominance Open
Background SARS-CoV-2 Omicron variants have increased vaccine-induced immune evasion and their emergence coincided with waning COVID-19 vaccine effectiveness (VE). The duration of immunity from the primary series and VE of booster doses ag…
View article: 496. Maternal Participation in Enrollment Interview and Risk of Bias in a Multicenter Pediatric Network Evaluating COVID-19 Vaccine Effectiveness in Infants
496. Maternal Participation in Enrollment Interview and Risk of Bias in a Multicenter Pediatric Network Evaluating COVID-19 Vaccine Effectiveness in Infants Open
Background The Overcoming COVID-19 network uses a case-control design to estimate effectiveness of maternal COVID-19 vaccination on COVID-19 associated hospitalization of infants. Vaccination history is asked in a maternal interview and ve…
View article: 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023
461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 Open
Background Immunocompromised (IC) persons are at increased risk of severe COVID-19 and can have a suboptimal immune response to a primary 2-dose COVID-19 vaccine series; thus, vaccination recommendations for IC persons include additional C…
View article: 2351. Concordance Between Sources of COVID-19 Vaccination Information Among Children Aged 5–18 years, May 2021–March 2023
2351. Concordance Between Sources of COVID-19 Vaccination Information Among Children Aged 5–18 years, May 2021–March 2023 Open
Background Documentation of COVID-19 vaccination is crucial for monitoring vaccine uptake and effectiveness. U.S. providers are required to document all COVID-19 vaccines administered in jurisdictional Immunization Information Systems (IIS…
View article: Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023
Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023 Open
View article: Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023
Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023 Open
Infants aged <6 months are not eligible for COVID-19 vaccination. Vaccination during pregnancy has been associated with protection against infant COVID-19–related hospitalization. The Overcoming COVID-19 Network conducted a case-control st…
View article: Pre-Delta, Delta, and Omicron Periods of the Coronavirus Disease 2019 (COVID-19) Pandemic and Health Outcomes During Delivery Hospitalization
Pre-Delta, Delta, and Omicron Periods of the Coronavirus Disease 2019 (COVID-19) Pandemic and Health Outcomes During Delivery Hospitalization Open
OBJECTIVE: To examine the relationship between coronavirus disease 2019 (COVID-19) diagnosis at delivery and adverse maternal health and pregnancy outcomes during pre-Delta, Delta, and Omicron variant predominance, with a focus on the time…
View article: Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023 Open
COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to …
View article: Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 Open
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In A…
View article: Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023
Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023 Open
Infants aged <6 months are not eligible for COVID-19 vaccination. Vaccination during pregnancy has been associated with protection against infant COVID-19-related hospitalization. The Overcoming COVID-19 Network conducted a case-control st…
View article: COVID-19-related Health Outcomes during Delivery Hospitalization During Pre-delta, Delta, and Omicron Periods
COVID-19-related Health Outcomes during Delivery Hospitalization During Pre-delta, Delta, and Omicron Periods Open
Background SARS-CoV-2 infection during pregnancy has been associated with several adverse maternal health and pregnancy outcomes; however, few studies have included pregnancies occurring during the time period of Omicron variant predominan…
View article: Development of Prototypical District-Scale Models: Preprint
Development of Prototypical District-Scale Models: Preprint Open
The U.S. has set the climate goal to achieve net-zero greenhouse gas emissions by 2050. District-scale solutions, which include scale-specific opportunities for energy and emissions savings, can be investigated and implemented to help acce…
View article: Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021–July 2022
Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021–July 2022 Open
Background Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly import…
View article: Development of prototypical district-scale models
Development of prototypical district-scale models Open
The United States has set the climate goal to achieve net zero greenhouse gas emissions by 2050. District-scale solutions, which include campus- and neighborhood-scale opportunities for energy and emissions savings, can be investigated and…